AAMC Home   Tomorrow's Doctors Tomorrow's Cures
  Home  Government Affairs   Newsroom   Meetings   Publications Shopping Cart   Site Map    

Home

Washington Highlights

Testimony & Correspondence

Top Issues:

 

Education

 

GME & IME Payments

HIPAA

Labor-HHS Appropriations

Research

Teaching Hospitals

Teaching Physicians

Veterans Affairs

Workforce

Government Affairs & Advocacy Site Map

Contact

 

Government Affairs Home > Washington Highlights > October 11, 2002

Kennedy Introduces Human Research Protections

October 11, 2002-Saying that "reforms are long overdue," Senator Edward Kennedy (D-Mass.) Oct. 4 introduced legislation calling for significant changes in the system of protections for human volunteers in research. The Research Revitalization Act of 2002 (S. 3060) would extend federal "Common Rule" regulations protecting human research participants to all research, regardless of funding source. The bill also provides statutory authority for the Office of Human Research Protections within the Department of Health and Human Services.

The bill includes a number of provisions targeted at improving the effectiveness of institutional review boards (IRBs), including:

  • requiring accreditation of all IRBs;
  • requiring investigators to notify IRBs if a research proposal has been rejected by any other IRB;
  • establishing rules for financial conflict of interest for IRB members;
  • allowing IRB expenses to be charged as direct costs on federal grants; and
  • allowing, on a voluntary basis, a central IRB to review projects conducted at multiple local research sites.

The bill strengthens current rules on financial conflict of interest for researchers, and establishes standards to govern payments to research subjects. The bill also requires HHS to establish a model program to train researchers in good research practices and then provide grants to allow universities to establish similar programs.

The bill calls for all human subject research conducted overseas that falls within US regulatory jurisdiction to be reviewed by a US-accredited IRB. The bill also requires rules governing the use of placebos or non-treatment when effective therapies could be administered to research subjects.

Noting that certain areas of research, such as gene therapy or xenotransplantation, raise unusual safety concerns, the bill requires special monitoring of adverse events in clinical trials of such research so that threats to patient safety can be identified.

Information:
Dave Moore, Senior Associate Vice President
AAMC Government Relations
dbmoore@aamc.org
(202) 828-0525

e-mail icon Get Washington Highlights in your Inbox!

Contact Us    © 1995-2008 AAMC    Terms and Conditions    Privacy Statement